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Abstract
Alzheimer’s disease (AD), the most common form of dementia in the aged 
people, is a chronic and irreversible neurodegenerative disorder. Early prediction, 
intervention, and objective diagnosis are very critical in AD. In this chapter, we 
will introduce the current progress in the prediction and diagnosis of AD, includ-
ing recent development in diagnostic criteria, genetic testing, neuroimaging 
techniques, and neurochemical assays. Focus will be on some new applied methods 
with more specific examples, that is, cerebrospinal fluid (CSF) and blood proteins 
and peptides, which might serve as biomarkers for the diagnosis of AD. We will also 
discuss biomarker-based diagnostic strategies and their practical application.
Keywords: Alzheimer’s disease, mild cognitive impairment, diagnosis, prediction, 
biomarker
1. Introduction
Alzheimer’s disease (AD), the most common type of dementia in aged people, 
is an untreatable neurodegenerative disorder characterized by abnormal accumula-
tions of amyloid-β (Aβ) oligomers and intracellular neurofibrillary tangles (NFTs) 
in the brain attributable to hyperphosphorylated tau that results in progressive syn-
aptic dysfunction and cognitive deficits [1, 2]. AD is the fifth leading cause of death 
for people aged 65 and over [3] and is officially listed as the sixth leading cause of 
death in the United States [4]. Presently, more than 47 million people are estimated 
to be living with dementia globally, and this number is projected to rapidly increase, 
reaching 75 million by 2030 and 135 million by 2050 [5]. In China, there were 
135.2 million aged people in 2015, and 8.5 million of them were oldest-old (beyond 
85 years and above). Based on age-specific prevalence of AD, China would have 
over 20 million AD patients in 2050 [6].
AD is a heterogeneous disease caused by a combination of environmental 
and genetic factors. Currently known risk factors for AD include age, sex, car-
diovascular risk factors and metabolic risk factors, sleep apnea, family history, 
and certain genetic variants [7]. In an attempt to explain the complexity and 
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multifactorial nature of AD, various hypotheses are established. These include Aβ 
aggregation, tau aggregation, metal dyshomeostasis, oxidative stress, cholinergic 
dysfunction, inflammation, and downregulation of autophagy [8]. However, none 
of the hypotheses is capable of independently explaining the pathological condi-
tions observed in AD. The amyloid cascade hypothesis is widely considered to be 
involved in the pathogenesis of AD [9]. The anatomic and temporal discordance 
between Aβ pathology, tau aggregation, and neurodegeneration has led to the pos-
tulation of Aβ being an initiator of a complex cascade that ends in tau-medicated 
neurodegeneration [7].
As the etiology and pathogenesis of AD have not been elucidated, none of the 
proposed pharmacologic treatments (medications) are authentic to slow or stop 
the neurodegeneration [10]. On the other hand, in clinical practice, a diagnosis of 
AD is primarily made on the base of clinical features, results of neurological and 
neuropsychological tests, and by exclusion of other causes of dementia, including 
vascular and frontotemporal dementia or other neurological diseases [11]. Although 
a variety of imaging techniques, and detection of levels of Aβ40, Aβ42, total tau 
protein (T-tau), and phosphorylated tau protein (P-tau) in CSF have been found 
to be able to support clinical diagnosis of mild cognitive impairment (MCI) and 
AD. However, CSF collection is invasive, and therefore, its sampling is quite dif-
ficult. Imaging techniques are expensive, which restrict their application either as 
routine screening tools or for repetition of tests to monitor the drug treatment or 
pathological progress [12].
The goal of precision medicine is to use biological knowledge and other related 
health information to predict individual disease risk, understand disease etiol-
ogy, identify disease subcategories, improve diagnosis, and provide personalized 
treatment strategies [7]. To date, none of the effective intervention is available, 
which can cure or halt the progression of AD. However, studies have consistently 
shown that active management of Alzheimer’s and other dementias can improve 
the quality of life of affected subjects and their caregivers [4]. The development of 
biomarkers for AD is making it possible to detect the disease and provide an accu-
rate diagnosis earlier, which is beneficial for diagnosed individuals, their caregivers 
and loved ones, as well as society as a whole [13]. In particular, pathophysiological 
alterations associated with AD are thought to begin several decades before the onset 
of the disease [14]. Thus, early diagnosis would provide a crucial opportunity for 
intervention in AD progression. In addition, the use of biomarkers in all stages 
of Alzheimer’s disease will facilitate to develop therapeutic strategy that targets 
the underlying brain changes at each stage. Moreover, the research of biomarkers 
discovery may contribute to enhance our understanding of the pathogenesis of the 
disease itself.
Therefore, the biomarker discovery is of utmost importance to improve diagnos-
tics and prevention of disease and to monitor treatment effects. In this chapter, we 
introduced the update of AD diagnostic criteria, genetic research, and imaging and 
fluid (CSF and blood) biomarkers, highlighting the progress of biomarker research 
and advances in methodology.
2. Advance in diagnostic criteria
2.1 Development of AD biomarkers in early guidance
The first set of criteria proposed for diagnosis of AD was launched in 1984 
by a workgroup from the National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s disease and Related Disorders Association 
3Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimer’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.82035
(NINCDS–ADRDA) [15]. At that time, Alzheimer’s pathological changes could 
not be measured in vivo. The criteria focused on clinical symptoms and required 
the presence of significant disability and impact on daily living. Thus, it allowed 
only a “probable” diagnosis of AD to be reached while the person was alive, and 
a definitive diagnosis could be made only if Alzheimer’s pathology was found at 
autopsy [15]. In terms of distinguishing AD from other types of dementia, its 
specificity was low [16]. In 2007, the AD Research Diagnostic Criteria proposed 
by the International Working Group (IWG) first included true biomarkers in the 
criteria for active diagnosis of AD and considered AD to progress from preclinical, 
pre-dementia to dementia [17].
In 2011, the National Institute on Aging and the Alzheimer’s Association 
(NIA-AA) proposed revised guidelines for diagnosing AD [18–21]. This updated 
diagnostic criteria and guidelines incorporated biomarker tests in addition to clini-
cal symptoms, and provided the researchers tools for diagnosing AD. It identified 
AD as a continuum with three distinct stages: preclinical stage, mild cognitive 
impairment (MCI), and dementia. There are two types of biomarker, the former 
including CSF Aβ42 or amyloid positron emission tomography (PET) and the latter 
including CSF tau/P-tau, MRI hippocampus or medial axillary atrophy, and low 
glucose metabolism on PET or SPECT [18]. In 2012, the NIA-AA also developed 
new guidelines to help pathologists to describe and categorize the brain changes 
associated with Alzheimer’s and other dementias on autopsy [22]. Parallel to the 
hypothetical pathophysiological sequence of AD, a biomarker model was proposed 
by Jack et al. [23, 24]. It revealed that the biomarker abnormality occurs first in 
Aβ levels, which can either be in the form of  an upregulation in plasma or down-
regulation in CSF in usually cognitively normal individuals and can be detected 
by biochemi cal analysis [6, 23, 24]. The next stage of biomarker abnormality was 
usually amyloid deposition in the brain detected by abeta PET. Subsequently, the 
changes of biomarkers include neuronal injury, indicated by increased levels of 
CSF total phosphorylated tau proteins, and cerebral atrophy revealed by structural 
MRI, as well as neurodegeneration and synaptic dysfunction detected by reduced 
fluorodeoxyglucose (FDG) uptake through PET. These results of biomarker studies 
showed that they are correlated with different disease stages, which thus correlate 
with and support the changes in the “abeta hypothesis” [6]. Furthermore, research 
criteria for diagnosing preclinical states of AD developed by the International 
Working Group (the IWG-2 criteria) require the individual to be asymptomatic 
and have a marker of AD pathology or an AD autosomal dominant mutation on 
chromosome 1, 14, or 21 [16]. This is describing an at-risk state where progression 
of AD is not inevitable.
2.2 NIA-AA 2018 update guidelines
Recently, NIA-AA guidelines for AD have been updated [25]. In these latest 
guidelines, Alzheimer’s biomarkers are divided into three categories (the A/T/N 
system). The classification uses three types of biomarkers as shown in Table 1. “A” 
refers to amyloid β (Aβ) as measured either by amyloid PET imaging of amyloid 
plaques or in the cerebrospinal fluid (CSF) as Aβ42 or the Aβ42 to Aβ40 ratio. “T” 
refers to tau pathology as measured by CSF phosphorylated tau or tau PET imag-
ing of parenchymal neurofibrillary tangles. “N” refers to neurodegeneration or 
neuronal injury and dysfunction, as measured by elevated levels of CSF total tau, 
decreased glucose metabolism shown on FDG-PET imaging, and brain atrophy 
shown with structural MRI. While “A” and “T” are considered to have diagnostic 
specificity for AD, “N” is not specific for AD diagnoses because it can reflect any 
number of etiologies in addition to AD. The A/T/N biomarkers may reflect the 
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presence (state) or progression (stage) of a disease. An individual with biomarker 
evidence of Aβ deposition alone (abnormal amyloid PET scan or low CSF Aβ42 or 
Aβ42/Aβ40 ratio) with a normal pathologic tau biomarker would be assigned the 
label “Alzheimer’s pathologic change” [25]. The term “Alzheimer’s disease” would be 
applied if biomarker evidence of both Aβ and pathologic tau is present. Alzheimer’s 
pathologic change and AD are not regarded as separate entities but earlier and later 
phases of the “Alzheimer’s continuum” (an umbrella term that includes both). These 
definitions are applied independently from clinical symptoms [25].
In addition, together with cognitive symptoms (C), AT (N)(C) measures have 
different roles for definition and staging, A and T indicate specific neuropathologic 
changes that define Alzheimer’s disease, that is, Aβ biomarkers determine whether 
or not an individual is in the Alzheimer’s continuum. Pathologic tau biomarkers 
determine if someone who is in the Alzheimer’s continuum has Alzheimer’s disease. 
(N) and (C) are not specific to AD and are therefore placed in parentheses. They 
indicate staging severity [25].
NIA-AA 2018 guidelines are still research framework and cannot be considered 
as routine clinical care [25]. However, clearly, with the update of these guidelines, 
the definition of AD shifts from symptom-based definition to biology-based defini-
tion. This is leading to a better understanding of the underlying mechanisms of 
the disease and aiding in the development of new interventions to delay or prevent 
disease progression and biomarker research [25].
3. Genetic susceptibility
AD can be divided into early-onset familial AD (EOAD) and late-onset AD 
(LOAD). Early-onset AD accounts for less than 1–5% and is caused by highly pen-
etrable variants, the majority of which are attributable to mutations in one of the 
three genes, amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 
2 (PSEN2) [26, 27]. Individuals with Alzheimer’s mutations in any of these three 
genes tend to develop symptoms before age 65, and the average age is 50 years [28]. 
More than 95% of AD cases are LOAD, which are “sporadic” with no apparent 
familial recurrence of the disease and are caused by a more complex underlying 
genetic architecture, and typically appear in older individuals (age 65 years and 
over) [29].
E4 allele of apolipoprotein E (APOE4) is the only verified genetic risk factor 
for late-onset AD. It is present in approximately 15% of the normal population; 
however, it occurs in 50% of those developing AD. APOE encodes a lipid carrier 
apolipoprotein E (ApoE) that is found both in the periphery and the central ner-
vous system [7]. APOE4 shows the complex interplay of mechanisms contributing 
to sporadic AD, including reduced cholesterol transport, less efficient Aβ clearance 
and more aggregation, triggering neurotoxicity through tau phosphorylation, 
increased brain neuronal activity and atrophy, reduced synaptic plasticity, and 
greater neuroinflammation [7].
Biomarker class CSF marker Imaging marker
Amyloid (A) CSF Aβ42,or Aβ42/Aβ40 ratio Amyloid PET
Tau (T) CSF phospho-tau Tau PET
Neurodegeneration (N) CSF total tau Anatomic MRI; FDG PET
Table 1. 
AT(N) biomarker grouping of the NIA-AA Framework.
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In addition to APOE4, genome-wide association study (GWAS) has identified 
more than 30 genomic loci that are associated with AD risk [7]. Ten susceptible 
loci for LOAD with the most consistent results include APOE, CLU, PICALM, CR1, 
BIN1, EPHA1, MS4A, ABCA7, CD33, and CD2AP. These AD risk loci are associ-
ated with different biological processes, including immune system, endocytosis, 
lipid homeostasis, and Aβ metabolism, highlighting the complexity of AD and 
point toward potentially novel directions for drug discovery and treatment [30]. 
Besides, rare variants (allele frequency < 1%) that influence the risk for LOAD have 
also been identified in several genes, including TREM2, PLD3, UNC5C, AKAP9, 
ADAM10, and ABI3 [7].
Genetics can provide a valuable starting point for advancement. To date, the 
vast majority of genetic work in AD has been the search for individual genes or 
combinations of genes associated with a dichotomous outcome of an AD diagnosis. 
For example, a study used survival analysis modeling to integrate AD risk variants 
and develop a polygenic hazard score for age of onset, which show a strong genetic 
component in AD that can be useful in predicting risk. Thus, genetic knowledge 
may also facilitate precision medicine. This approach has recently been proposed for 
dementia [7].
4. Biomarkers of AD
4.1 Imaging
As mentioned above, three Alzheimer’s neuroimaging biomarkers are currently 
used for research and, in some cases, are used to aid in clinical diagnosis. Elevated 
cortical tau shown with PET imaging is a biomarker for neurofibrillary tangles; 
decreased glucose metabolism shown by FDG-PET imaging and atrophy shown 
by structural MRI are biomarkers for neurodegeneration or neuronal injury [31]. 
Deposition of Aβ can be detected by amyloid-specific imaging agents for positron 
emission tomography-computed tomography (PET/CT) as early as 15 years before 
the onset of AD symptoms, whereas the next most sensitive metric, cerebral hypo-
metabolism (FDG-PET/CT) is detectable only 10 years prior to symptom onset. Aβ 
PET/CT is thought to precede by 10 years the declines in even the most sensitive 
cognitive metrics including episodic memory [32].
4.2 Fluid biomarkers for AD
In parallel to imaging biomarkers, additional types of biomarkers currently 
being studied in AD and used mainly for research purposes are found in CSF and 
blood.
4.2.1 CSF biomarker
The most validated CSF biomarkers for AD are Aβ42, total tau (T-tau), and tau 
phosphorylated at threonine 181 (P-tau181) [33]. These biomarkers have consis-
tently shown a marked change in AD dementia and also in the early prodromal 
phase of the disease. In CSF of AD patients, a decreased level of Aβ42 has consis-
tently been found, whereas the concentrations of tau and P-tau are increased [33]. 
The levels of CSF tau and P-tau have been found to correlate with brain atrophy in 
AD, while a reduction of Aβ42 in CSF is shown to correlate with brain atrophy in 
non-demented subjects indicating a potential preclinical stage [34]. In addition, 
high CSF T-tau and P-tau predict the progression of cognitive symptoms better 
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than Aβ42 during a clinically relevant time period (1–2 years) [35]. Based on their 
high diagnostic performance, as state above, these core AD CSF biomarkers have 
been included in the diagnostic criteria for AD [18, 25]. However, CSF biomarkers 
show 20–30% interlaboratory and interassay variability [36]. In order to reduce 
this variability, standardization efforts include the creation of a mass spectrom-
etry (MS)-based reference measurement procedures (RMP) for CSF Aβ42 [37] 
and certified reference materials (CRM) for the main AD CSF biomarkers [38]. 
Precise measurements have also been achieved by novel assays developed on fully 
automated laboratory equipment [39]. Moreover, other Aβ protein levels and ratios 
(tau/Aβ42, Aβ42/Aβ40, Aβ42/Aβ38) also become abnormal with the signature of AD 
[40]. For example, reduced Aβ42/Aβ40 ratio is characteristic of AD dementia and 
prodromal AD [41].
Despite the promising CSF core biomarkers for the identification of presymp-
tomatic AD and discriminate AD cases well from healthy subjects, the inherent 
heterogeneity in the progression of mounting plaque and tangle load over time 
between patients, as well as the presence of mixed pathologies and different 
comorbidities, are considered [42]. For example, elevated amyloid deposition 
is frequently found in cognitively normal subjects, and CSF levels of Aβ and Aβ 
imaging with PIB-PET do not correlate with cognitive decline [43]. Thus, it is 
needed to augment the CSF core biomarkers with novel proteins to improve diag-
nostic accuracy in longitudinal studies [44]. Recently, new biomarkers reflecting 
other aspects of pathophysiology have been reported, for example, CSF neuro-
filament light chain (NFL), neurogranin, and YKL-40 proteins have reached at 
an advanced clinical validation stage [45]. A recent meta-analysis showed that 
the core CSF biomarkers of neurodegeneration (T-tau, P-tau, and Aβ42) and CSF 
NFL were strongly associated with AD, and NSE, VLP-1, HFABP, and YKL-40 
were moderately associated with AD [33]. Among these, NFL, NSE, VLP-1, and 
HFABP are related to neurodegeneration, and YKL-40 is associated with glial 
activation [33]. Of note, another protein, neuro granin, involved in synaptic 
dysfunction and degeneration, is found with higher CSF levels in patients with 
AD. It is seemingly specific for AD and does not change in the majority of other 
neurodegenerative disorders [35]. Taken together, the integration of comple-
mentary pathophysiological biomarker candidates covering additional key AD 
mechanisms will likely result in an incremental performance optimization for the 
detection, diagnosis, and differential diagnosis of primary neurodegenerative 
diseases and dementia disorders [45].
4.2.2 Blood-based biomarker
Blood collection is routinely performed, minimally invasive and cheap and 
suitable for recurrent measures. Blood-based biomarkers may allow for efficient 
monitoring of disease processes in AD and could be used as a screening tool in 
primary care [46]. Amyloid β (Aβ) is a widely researched plasma biomarker for 
AD. Evidence supporting the transport of Aβ across the blood-brain barrier and 
through CSF suggests that 30–50% of plasma Aβ originates from the CNS [47]. 
However, diagnostic relevance of plasma Aβ for AD process yields conflicting 
results [33, 48, 49]. In terms of this, a meta-analysis found that lower Aβ42:Aβ40 
ratios are significantly associated with the development of AD and dementia 
[49]. Another meta-analysis showed that plasma or serum concentration of 
Aβ40 did not differ significantly between patients with AD subjects and controls 
[33]. Recently, using the INNO-BIA kit based on a multiplex xMAP technique, 
Hanon et al. found that plasma Aβ42 and Aβ40 are lower in AD than in amnestic 
MCI and non-amnestic MCI, respectively. Plasma Aβ42 correlated with age, 
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Mini–Mental State Examination, and APOE ε4 allele [48]. Another AD pathol-
ogy, that is, tau, a meta-analysis suggested that plasma T-tau are strongly associ-
ated with AD [33].
Indeed, CNS-specific proteins with very low concentrations in the blood are 
difficult to quantify using standard immunochemical technologies, such as ELISA 
(enzyme-linked immunosorbent assay), which is a major challenge in developing 
blood biomarkers [20]. This might be one of the reasons for the inconsistency of the 
analysis results in the previous studies. Recent technical breakthroughs in the field 
of ultrasensitive assays have started to improve it [50]. These technologies include 
single-molecule array (Simoa) technology and immunomagnetic reduction (IMR) 
[50]. Simoa technology can detect single protein molecules in blood, which cap-
tured target proteins on microscopic beads decorated with specific antibodies and 
then labeled the immunocomplexes (one- or zero-labeled target protein molecules 
per bead) with an enzymatic reporter capable of generating a fluorescent product. 
After isolating the beads in 50-fl reaction chambers designed to hold only a single 
bead, fluorescence imaging is detected [51]. The average sensitivity improvement of 
the Simoa immunoassays versus conventional ELISA was >1200-fold, with coef-
ficients of variation of <10% [52]. By using this technique, Mattsson et al. found 
associations between elevated plasma tau and AD hallmarks, but these were mild 
and differed between cohorts, and high plasma tau is associated with rapid progres-
sion in later disease stages [53]. More recently, by using this platform, Tatebe et al. 
reported the quantitative data on the plasma levels of P-tau181 in controls and 
patients with AD and Down syndrome (DS). These data suggest that the plasma 
P-tau181 is a promising blood biomarker for brain AD pathology [54]. Mielke 
et al. reported that plasma total tau and P-tau181 levels are higher in AD dementia 
patients than those in cognitively unimpaired and total tau and P-tau181 levels are 
higher in AD dementia patients than those in cognitively unimpaired, and plasma 
P-tau181 are more strongly associated with both Aβ and tau PET [55]. Interestingly, 
the neuronal injury marker NFL mentioned above was also found to be increased in 
plasma of the patients with MCI and patients with AD dementia with Aβ pathologic 
features by using Simoa technology [46].
Another ultrahigh-sensitive technology is referred to as a superconducting 
quantum interference device (SQUID) immunomagnetic reduction (IMR) assay. 
Magnetic nanoparticles are coated with an antibody, and on binding of the analyte, 
the oscillation of the particles in an alternating magnetic field is decreased in a 
concentration-dependent manner [56]. Using the SQUID-based IMR, the low 
detection limit for amyloids and tau protein is found to be 1–10 pg/mL [57, 58]. 
Thus, it makes possible the measurement of plasma biomarkers for the diagnosis 
of AD [58–61]. For example, by IMR technology, the previous studies suggested 
that the plasma Aβ42 is a useful biomarker for AD. The Aβ42/Aβ40 ratio improves 
the diagnostic power of the plasma Aβ biomarkers [58], and plasma Aβ42 correlates 
with CSF Aβ42 in AD [59]. Additional researches indicated that plasma Aβ42 and tau 
can be used to assist in the clinical diagnosis of AD [60], and the concentration of 
P-tau181 in plasma can be used to differentiate memory disorder/cognitive decline 
in early-stage AD patients [61]. Clearly, these ultrahigh-sensitive assay technologies 
provide novel methods to measure low-level proteins especially in blood. These 
AD-specific proteins such as Aβ, and tau-related proteins or the protein biomarkers 
at low concentrations in the bloodstream for AD and may serve as clinical tools for 
the diagnosis of AD.
Besides, the studies of blood-based biomarkers also cover the following aspects: 
searching for other disease pathology related to proteins in blood; blood-based 
biomarker panels; and markers of inflammation, oxidative stress, mitochondrial 
dysfunction, and neuronal and microvascular injury [62].
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5. Mass spectrometry (MS)-based methods and approaches
Numerous reports have demonstrated that MS-based methods can be robust, 
and accurate MS has been playing an important role in studying peptide and protein 
identities, structures, modifications, and interactions that collectively drive their 
biological functions. MS-based technology has been used to study the pathogenesis 
of AD and biomarkers in body fluids, such CSF, plasma, urine, and saliva.
5.1 Proteomics
MS-based proteomics technology is well suited for the biomarker discovery for 
diseases such as AD [63–65]. During the last 10 years, apart from the gel-based 
techniques (e.g., 2D-PAGE and 2D-DIGE), gel-free techniques (e.g., stable isotope 
labeling or using label-free methods) have been dominating the field of MS-based 
quantitation in proteomics [66]. Including our previous study [67], the method 
of iTRAQ with multidimensional liquid chromatography and tandem mass spec-
trometry has been used to reveal many candidate proteins as potential biomarkers 
of MCI or AD [67–69]. One of our quantitative proteomics-based studies revealed 
the differentially expressed proteins in AD subjects [67]. These proteins were found 
involved in various biological processes and pathways, such as Aβ metabolism, 
inflammatory and immune response, and oxidative stress, which have previously 
been reported to be linked with AD, supporting the existing theories of AD patho-
physiology. Furthermore, some new technologies such as SWATH-MS will also be 
applied to further enhance probability of AD biomarkers. SWATH-MS is a specific 
further variant of data-independent acquisition (DIA) methods and is emerging as 
a technology that combines deep proteome coverage capabilities with quantitative 
consistency and accuracy [70].
Apart from quantitative proteomics, the development of assays to quantify 
particular post-translational modification of proteins is also being considered [65, 
71, 72]. For example, the carbonylation of proteins associated with oxidative stress 
has been studied in AD [72]. Using Western blotting with two-dimensional gel elec-
trophoresis (2D-Oxyblot), we investigated the specifically carbonylated proteins 
in the hippocampi [73] and serum [74] of triple transgenic mouse model of AD 
(3 × Tg-AD) at the early age of month, some carbonylated proteins were identified 
as significantly oxidized proteins compared with the control in both of the samples. 
This suggests that oxidative stress is an early event in AD progression, and these 
oxidized proteins in the serums may provide potential biomarkers of AD at the early 
stage. This is similar to two previous studies [75, 76]; where the authors observed 
serum protein carbonylation in MCI and found increased levels of carbonylation at 
this stage of cognitive decline.
Together, the proteomic approach is comparatively new and more advanced for 
biomarker analysis of proteins and provides a complementary way to obtain such a 
comprehensive data.
5.2 Targeted proteomic approaches
There are generally three different stages in the development of new biomark-
ers: the discovery phase (i.e., screening), the verification phase, and the validation 
phase. Multiple reaction monitoring (MRM), also known as selected reaction 
monitoring, is a targeted mass spectrometry approach to protein quantitation and 
is emerging to bridge the gap between biomarker discovery and clinical validation 
[77, 78]. Highly multiplexed MRM assays are readily configured and enable simul-
taneous verification of large numbers of candidates facilitating the development 
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of biomarker panels which can increase specificity [77, 78]. MRM can enhance the 
lower detection limit for peptides due to its ability to rapidly and continuously mon-
itor exclusively for the specific ions of interest. MRM analysis combine with stable 
isotope also offers multiplexing capability and increases the reliability of quantifi-
cation [77, 78]. As AD is a multifactorial disease, a panel of proteins is more suitable 
as biomarker for AD. Thus, MRM is a valuable tool to verify biomarker candidates 
for AD and possible future practical applications. Several studies have emerged 
using MRM to identify CSF-based protein biomarkers of AD [79–81]. In addition to 
MRM, parallel reaction monitoring (PRM) technique has also been used to evaluate 
biomarker candidates for AD [82, 83]. PRM is related to the SRM approach but has 
the advantage of acquiring full fragment spectra instead of a choice of preselected 
fragments; interfering signals are avoided, whereas quantitation and high sensitiv-
ity are conserved [64]. In this way, other biochemical pathways and proteins which 
are not directly correlated to Aβ accumulation could be monitored, such as synaptic 
function, secretory vesicle function, and in the innate immune system.
5.3 Immunoprecipitation (IP) methods coupled with mass spectrometry
Due to wide dynamic range and low abundance of Aβ peptides, the most com-
mon experimental procedure to quantitate Aβ peptides in CSF or blood requires 
a sample preparation step before MS analysis. Many methods are currently avail-
able to purify/concentrate the Aβ peptides, such as solid-phase extraction (SPE), 
immunoprecipitation (IP), size exclusion, ultrafiltration and liquid-liquid extrac-
tion, immunodepletion, etc. [64]. Among these, IP is a common method. By using 
IP coupled with SRM-MS method, a recent publication reported that plasma Aβ42 
concentration correlated with the CSF Aβ42/Aβ40 ratio and had good accuracy 
for predicting the sensitivity and specificity of elevated brain Aβ [25]. Similarly, 
Nakamura et al. recently proposed a set of plasma biomarkers, the amyloid-β pre-
cursor protein (APP) 669–711/Aβ42 and Aβ40/42 ratios and their composites, for AD 
diagnosis with high sensitivity and specificity. Their composites displayed an accu-
racy of 90% in predicting Aβ brain burden at an individual level, as confirmed with 
PET imaging [84]. Of note, as reviewed by Brinkmalm et al. [85], in normal APP 
and Aβ metabolism, Aβ is most likely regulated by amyloid-degrading enzymes 
[86]. Different lengths of Aβ peptides exist in vivo, depending on different degra-
dation pathways of APP [87]. To date, more than 40 different endogenous APP and 
Aβ peptides, including modifications, have been identified in the CSF [88]. Thus, 
these approaches can not only give a more accurate quantification of Aβ peptides in 
blood or CSF but also can be used to detect various Aβ species, which are beneficial 
to screen candidate biomarker for AD. For example, using the high selectivity 
of anti-Aβ antibodies in combination with mass spectrometry to determine the 
molecular mass with high accuracy, Vigo-Pelfrey et al. demonstrated the complex 
nature of Aβ peptides in the CSF and reported several different N- and C-terminal 
variants of Aβ [89]. In addition, IP-MS method has also been used to measure the 
protein levels in the CSF; using this method, a marked increase in the CSF levels of 
both synaptosomal-associated protein 25 (SNAP-25) and synaptotagmin-1 (SYT1) 
was found in AD dementia and prodromal AD cases [90, 91]. Interestingly, the 
levels of both SNAP-25 and SYT1 are reduced in cortical areas in the AD brain [90], 
thus suggesting that a set of synaptic proteins covering different components of the 
synaptic unit may be valuable tools in clinical studies on the relevance of synaptic 
dysfunction and degeneration in AD pathogenesis. This may also be used in the 
clinical evaluation of patients. The results indicate that this strategy is advantageous 
for detecting low abundance proteins, especially from CNS, or various Aβ peptides 
as a biomarker of AD.
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6. Other technologies and methods
6.1 Metabolomics
Metabolomics is the newest omics platform that offers great potential for the 
diagnosis and prognosis of neurodegenerative diseases. This reflects alterations in 
genetics, transcription, and protein profiles and influences from the environment. 
Mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy 
are two analytical platforms regularly used for detection. NMR is a particularly 
powerful tool for metabolite structural test. An MS-based approach is a sensitive 
one to identify and quantify in complex biological systems [65]. Metabolomics 
encompasses several techniques including untargeted metabolomics, targeted 
metabolomics, lipidomics, and fluxomics [92–94]. Untargeted metabolomics 
measures hundreds of metabolites in order to identify metabolic signatures related 
to a particular disease state or phenotype. This approach provides relative changes 
in metabolites and is useful for discovery projects where affected metabolic path-
ways are unknown. Targeted metabolomics provides quantitative measurements of 
a defined set of metabolites in a pathway of interest (e.g., glycolysis or TCA cycle). 
Lipidomics estimates changes in lipid profiles and requires specialized protocols for 
the detection and analysis of water-insoluble metabolites. Fluxomics incorporates 
stable isotope tracers to provide a dynamic, as opposed to static, assessment of 
metabolic changes and is performed in cells or in vivo [95]. Metabolomics has been 
widely used in the study of mechanisms and biomarkers of Alzheimer’s disease. 
Metabolomics analysis conducted with biological samples of patients with MCI 
and AD identified metabolic changes associated with preclinical and clinical AD, 
such as plasma, CSF, and saliva (Table 2) [95–104]. These findings suggest that 
metabolomics-based biomarkers could be used to improve disease diagnosis, which 
will allow target pathways altered earlier in AD.
6.2 MicroRNA (miRNA)
miRNAs are a class of small non-coding RNAs of 20–22 nucleotides in length, 
which regulate more than 50% of protein-coding genes [105], and are associated 
with many neurodegenerative diseases, such as AD [106]. Fransquet and Ryan 
comprehensively reviewed the methods and findings from 26 studies comparing 
the measurement of miRNA in blood between AD cases and controls [107]. Of 8098 
individually measured miRNAs, 23 that were differentially expressed miRNAs were 
found to be significant in two or more studies. Only six miRNAs (miR-107, miR-125b, 
miR-146a, miR-181c, miR-29b, and miR-342) were consistent in their direction of 
expression between these studies [107]. Interestingly, miR-107 has been found to be 
associated with the dysregulation of proteins involved in aspects of AD pathology, as 
well as being consistently downregulated in AD brains [107].Thus, the differentially 
expressed miRNAs and the corresponding targets will be potential biomarkers and 
provide evidence for new strategies for design of drugs for AD treatment.
6.3 Exosomes
Exosomes contain proteins, messenger RNAs (mRNAs), and microRNAs 
(miRNAs) that reflect their cellular origin, and they play a prominent role in 
cellular signaling, expulsion of toxic proteins, and transfer of cellular pathogens to 
other cells. CNS-derived exosomes (NEDs) are present in biological fluids (blood, 
CSF, and urine) and circulate in the interstitial space, both in the brain and in the 
periphery [108]. It may serve as markers of underlying CNS changes that occur in 
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advance of changes in circulating proteins. Importantly, CNS-derived exosomes 
have unique surface markers that reflect their origin. By using the correspond-
ing anti bodies, targeted examinations of neuron-, astrocyte-, or endothelial cells 
can be performed (Table 3) [109–113]. Several proteins in neural-derived plasma 
exosomes have been identified to associate with preclinical AD [112], and cargo 
proteins of plasma astrocyte-derived exosomes in AD have also been detected [110]. 
Interestingly, alterations in plasma NDE levels of P-tau, Aβ42, neurogranin, and 
repressor element 1-silencing transcription factor were found among AD and MCI 
cases that converted to AD within 36 months compared with stable MCI cases and 
normal control subjects [113]. In addition, miRNAs released from exosomes appear 
to be associated with multiple neurodegenerative conditions linking to AD, which is 
marked by hyperphosphorylated tau proteins and accumulation of Aβ plaques [114]. 
Category Samples Methods Candidate metabolitesa References
Untargeted 
metabolomic
Plasma UPLC/HILIC 
-QTOF-MS
All groups: 4-aminobutanal ↓, 
spermine ↑
L-arginine ↑ L-ornithine ↑
[96]
Lipidomic Plasma UPLC-MS Ceramides ↑: Cer16:0 Cer18:0, 
Cer24:1
Phosphatidylcholines ↓: PC36:5, 
PC38:6
[97]
Lipidomics Plasma UPLC-QTOF-MS Phosphatidylcholine 40:4 ↑
Triglyceride 57:1 ↓
ChoE/triglyceride ↓
[98]
Targeted 
metabolomics
Serum UPLC-TQ-S-MS/
MS
Aβ pathology ↑: PCs and SMs
Tau pathology ↑: long-chain 
acylcarnitines,
PC ae C36:2, and SM.C20:2
[99]
Untargeted 
metabolomics
Serum FIA-MS/MS
UPLC-MS/MS
Glycerophospholipids ↓
Sphingolipids ↑
[100]
Untargeted 
metabolomic
Saliva FUPLC-Q-TOF/
MS
Phenyllactic acid ↑ 
hypoxanthine ↓
Sphinganine-1-phosphate ↑
Ornithine ↑, inosine ↓
3-Dehydrocarnitine ↓
[101]
Targeted 
metabolomic
Saliva 1H NMR Propionates ↑ [102]
Untargeted 
metabolomics
CSF UPLC-MS/MS S-adenosylhomocysteine ↓, 
glycine ↓,
S-adenosylmethionine ↑
[103]
Targeted 
metabolomics
PCSF FMOC-derivatized
UHPLC-MS/MS
Methionine sulfoxide ↑, 
guanine ↑,
Anthranilate ↓, 
diacetylspermine ↓,
3-Methoxy-anthranilate ↑,
Cadaverine ↑, histamine ↑,
3-HydroxyKynurenine ↓
[104]
Abbreviations: Cer: Ceramides; ChoE/TG: indicates co-elution of ChoE and TG molecules; FIA-MS/MS: flow 
injection analysis-MS/MS; FMOC: 9-fluorenylmethyl chloroformate; FUPLC: faster ultra-performance liquid 
chromatography; HILIC: hydrophilic interaction liquid chromatography; MS: mass spectrometry; NMR: nuclear 
magnetic resonance; PC: Phosphatidylcholines; PCSF: Postmortem cerebrospinal fluid; SM: sphingomyelin; TOF: 
Time of flight; UPLC: high-performance liquid chromatography.
aCompared with the control: ↑: upregulated; ↓: downregulated.
Table 2. 
AD-related metabolomics studies reported in the literatures.
Molecular Medicine
12
Specific profiles of exosomal miRNAs from human biological fluids, such as 
plasma and CSF, have prompted the potential application of miRNAs as diagnostic 
 biomarkers (Table 3) [115–118]. These findings further support the search of 
exosome-based biomarkers for AD and other neurodegenerative diseases.
Samples Materials Exosomes-proteins/
miRNAsa
Methods References
AD = 57
Control = 57
Plasma Total tau ↑
P-T181-tau ↑
P-S396-tau ↑
Aβ1–42 ↑
ELISA [109]
AD = 12
Control = 10
Plasma GDNF ↓
P-T181-tau ↑
BACE-1 ↑
sAPPβ ↑
P-S396-tau ↑
ELISA [110]
AD = 26
Control = 26
Plasma P-serine-312-IRS-1 ↑ ELISA [111]
AD = 46
Control = 46
Plasma LAMP-1 ↑,
Ubiquitin ↑,
HSP70 ↓.
ELISA [112]
AD = 10
MCI = 20
Control = 10
Plasma P-T181-tau ↑
P-S396-tau ↑
Aβ1-42 ↑
NRGN ↓
REST ↓
ELISA [113]
MCI = 43
DAT = 51
Plasma, 
CSF
mir-193b ↓ qPCR, WB [115]
AD = 50
Control = 50
Plasma mir-342-3p ↓
mir-342-5p ↓
mir-23b-3p ↓
mir-24-3p ↓
mir-338-3p ↓
mir-3065-5p ↓
MicroRNA
sequencing
[116]
AD = 28
Control = 27
CSF mir-29c ↓
mir-136-3p ↓
mir-16-2 ↓
mir-331-5p ↓
mir-485-5p ↑
miRNA assay
qPCR
[117]
Health  
Control = 23/36
MCI = 3/8
AD = 23/16
Serum Fold change > 1.5
Adjust p-value < 0.05 (HC 
vs AD):
hsa-miR-20a-5p ↑
hsa-miR-3065-5pb ↑
hsa-miR-582-5p ↑
Fold change < 0.83
Adjust p-value < 0.05 (HC 
vs AD):
hsa-miR-342-3p ↓
hsa-miR-1306-5p ↓
RT-qPCR
Deep 
sequencing
[118]
Abbreviations: BACE-1: β-site amyloid precursor protein-cleaving enzyme 1; DAT: dementia of Alzheimer type; 
GDNF: glial-derived neurotrophic factor; HSP70: heat-shock protein 70; IRS: insulin receptor substrate; LAMP-1: 
lysosome-associated membrane protein 1; NRGN: neurogranin; REST: repressor element 1-silencing transcription 
factor; WB: Western blot analysis; RT-qPCR: Reverse transcription-quantitative real-time PCR.
aExpression changes in AD, compared with the control: ↑: upregulated; ↓: downregulated.
Table 3. 
AD-related CNS-derived exosomes (proteins/miRNAs) reported in the literatures.
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7. Conclusions
AD is the most common type of dementia and is becoming a major challenge for 
global health and social care. The last 20 years have seen an enormous expansion 
in research on biomarkers for AD. The use of biomarkers, such as T-tau, P-tau, and 
Aβ42 (and Aβ42/Aβ40 ratio), together with brain imaging now provides the ability 
to detect evidence of the AD pathophysiological process in vivo. However, CSF 
biomarker and brain imaging are not used as screening tools. Research efforts have 
focused on the development and validation of non-invasive blood-based biomark-
ers. Recent advances in technical developments of novel ultrasensitive immunoas-
say, mass spectrometry methods, metabolomics, and exosomes show promise for 
blood biomarkers with potential applications as screening tools for AD (Figure 1). 
These opened a window for the study of AD biomarkers.
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